论文部分内容阅读
Atazanavir是一种对HIV -1蛋白酶具有高度活性和特异性的新的氮杂肽 (azapeptide)类蛋白酶抑制剂 ,其耐药性与其它蛋白酶抑制剂显著不同 ,与其耐药性相关的最突出的病毒基因型变化为I5 0L(即第 5 0位密码子由异亮氨酸变成了亮氨酸 )。Atazanavir可每日口服一次 ,是肝脏细胞色素P45 0酶系的中度抑制剂。与司他夫定和去羟肌苷联用 ,atazanavir迅速、有效并且持续地降低病毒负荷。治疗 10 8周后不升高总胆固醇 (TC) ,低密度脂蛋白 (LDL -C)和甘油三酯 (TG)水平 ,其与治疗方案相关的发生率最高的不良反应为恶心
Atazanavir is a novel azapeptide-like protease inhibitor that is highly active and specific for HIV-1 protease and its resistance is significantly different from that of other protease inhibitors, with the most prominent The virus genotype changed to 150 μL (ie, the codon at position 50 changed from isoleucine to leucine). Atazanavir can be taken orally once daily as a moderate inhibitor of the liver cytochrome P45 0 enzyme system. In combination with stavudine and didanosine, atazanavir rapidly, effectively and consistently reduces viral load. After 10 weeks of treatment, the levels of total cholesterol (TC), low density lipoprotein (LDL-C) and triglyceride (TG) were not elevated and the most frequent adverse reactions associated with the treatment regimen were nausea